SCHEMBL3345280

SCHEMBL3345280

CC1(C)CCC(NCc2cc(-c3cccc(NC(=O)C(F)(F)F)c3)cs2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
PAX8 Q06710 2/20 0.40
MEN1 O00255 1/20 0.40
HSP90AA1 P07900 1/20 0.40
KMT2A Q03164 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
HDAC1 Q13547 2/20 0.37
HDAC7 Q8WUI4 2/20 0.37
HDAC8 Q9BY41 2/20 0.37
HDAC6 Q9UBN7 2/20 0.37
STS P08842 1/20 0.35
CNR1 P21554 1/20 0.35
MGLL Q99685 2/20 0.34
KDM4E B2RXH2 1/20 0.34
HDAC3 O15379 1/20 0.34
HDAC4 P56524 1/20 0.34
HDAC2 Q92769 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3345082 0.89 MEN1 (0.36) NPC1RAB9AMEN1KMT2AL3MBTL1
Trifluoroacetic Acid SCHEMBL3345276 0.81 OPRM1 (0.40) HDAC6MGLLEGLN1FAAH
SCHEMBL3345300 0.81 NPC1 (0.42) NPC1RAB9APAX8MEN1HSP90AA1
SCHEMBL12651152 0.79 OPRM1 (0.44) HDAC6MGLLFAAH
SCHEMBL3345320 0.78 NPC1 (0.47) NPC1RAB9APAX8MEN1HSP90AA1
Trifluoroacetic Acid SCHEMBL3345080 0.76 OPRM1 (0.41) HDAC1HDAC8HDAC6
SCHEMBL3339287 0.74 GRIA2 (0.46) NPC1RAB9APAX8MEN1HSP90AA1
SCHEMBL12651056 0.74 OPRM1 (0.46) HDAC1
SCHEMBL1788607 0.70 OPRM1 (0.42) L3MBTL1MAPTHDAC1POLBLMNA
Trifluoroacetic Acid SCHEMBL3340376 0.68 ALDH1A1 (0.47) NPC1MEN1KMT2AMAPTHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors GLAXOSMITHKLINE LLC 2014-10-30 US disclosed
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS IGNAR DIANE MICHELE 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113512-A1 METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS OPRL1, OPRD1, OPRK1 NPC1 3112/4885RAB9A 2340/4885PAX8 1560/4885
US-20140323487-A1 Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors OPRL1, OPRM1, OPRK1 NPC1 3467/4885RAB9A 1186/4885PAX8 939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.